SERO
Quality control materials for clinical laboratories, produced for IVD makers and medical labs worldwide
Highlights
- New on EvolcAdded 2026-10-28
About SERO
SERO produces human-based quality control (QC) materials for clinical laboratories, including liquid and freeze-dried immunoassay, clinical chemistry, cardiac and urine controls sold under the Seronorm and Autonorm brands.
Its customers include IVD manufacturers, hospital and large international laboratory organisations, and distributors. The company sells directly in the Nordic countries and through partners in more than 60 countries, and it describes its production as the only activity of the company.
The company was founded in 1963 in Norway by Professor Dr. med. Lorentz Eldjarn and is headquartered in Billingstad. It is family-owned and reports a yearly production of more than 2 million vials. The website lists trade-fair and congress participation and includes a careers section.
Product: Seronorm and Autonorm human-based liquid and lyophilised quality control materials for immunoassay, clinical chemistry, cardiac and urine testing.
Public tenders won
4 tenders won since 1 Jan 2024 from 4 public buyers in Norway, Sweden, worth 10.4M SEK + 2.5M NOK as awarded. From EU award notices (TED) that name SERO by its registry number.
- 17 Apr 2026 Västra Götalandsregionen · Kontroller för kemi/immunkemi notice
- 9 Apr 2026 Oslo Universitetssykehus HF (hovedenhet) · 77491 RA KLM Department for Medical Biochemistry Analysis Instrument FIT · 2.5M NOK notice
- 14 Jan 2025 Region Gävleborg · Kontroller till analysarbete · 8.0M SEK notice
- 23 Apr 2024 Region Jönköpings Län · Kontrollmaterial Laboratoriemedicin · 2.4M SEK notice
Jobs at SERO
Leadership
- Lorentz Eldjarn · Founder (Professor Dr. med. Lorentz Eldjarn)Source: company website
More biotech & pharma companies
STIM
Supplies vaccines, medicines and fish health products and provides inspection and marine monitoring for Norwegian aquaculture farmsNew on EvolcThor Medical
Produces thorium-derived alpha-particle emitters for makers of radioligand cancer therapies and research usersNew on EvolcTribune Therapeutics
Preclinical biopharma developing anti-fibrotic medicines that target CCN signaling, for patients with fibrotic diseaseNew on EvolcVESO
Fish and animal health products, contract trials and veterinary medicines for aquaculture and veterinary customers in NorwayNew on EvolcVitas
Contract analytical lab in Oslo running DBS biomarker analysis and GMP pharma quality testing for drug, food and research clientsNew on EvolcZelluna
Clinical-stage biotech developing TCR-guided NK cell therapies for solid cancers, led by ZI-MA4-1 in a Phase 1 trialNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Google Tag Manager
- Next.js
- React
- Sanity
- Tailwind CSS
- Vercel